Positive Proof of efficacy results from Dengue Vaccine - But hurdles still persist!!!
Today Sanofi reported positive proof of efficacy and safety data for tetravalent Dengue vaccine. Although the data supports efficacy, but falls short of winning investor’s conviction, as evidence of efficacy was observed only in three out of the four serotypes, despite antibody response for all four serotypes. According to NIH Research “Someone who has antibodies against only one or a few of the virus serotypes is actually at higher risk of developing the severe form of the disease upon infection by another serotype”. The complexity of the desired effectiveness from vaccine actually depends on the protection from all strains.
COMPANIES MENTIONED
Sanofi
Sanofi
